LearnGlossaryMarketStocksSuperinvestorsSign in

TSHA

Taysha Gene Therapies, Inc.

Healthcare · $1.6B market cap

Verdict

We can't put a fair value on TSHA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-38.8% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-51.6%✗

Follow TSHA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds TSHA. In Q2 2026, 1 added. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$3.3M

489,219 shares

Moves in Q2 2026

Added: Polen Capital Management

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works